Reconversión integral del modelo turístico de la Platja de Palma

XII Coloquio de Geografía del Turismo, Ocio y Recreación de la Asociación de Geógrafos Españoles. Colmenarejo (Madrid), del 17 al 19 de junio de 2010.Publicad

Aptitudes de Palma (Mallorca) como ciudad de turismo urbano y cultural

XII Coloquio de Geografía del Turismo, Ocio y Recreación de la Asociación de Geógrafos Españoles. Colmenarejo (Madrid), del 17 al 19 de junio de 2010

Evolución y cambios formales y funcionales de las imágenes promocionales turísticas en las Islas Baleares

XII Coloquio de Geografía del Turismo, Ocio y Recreación de la Asociación de Geógrafos Españoles. Colmenarejo (Madrid), del 17 al 19 de junio de 2010

Interação de derivados de benzenossulfonamida com Smyd3 usando um modelo teórico

Cancer is a serious public health problem worldwide. This clinical pathology is associated with the activation/release of several biomolecules, including the Smyd proteins family. In this way, some studies indicate that Smyd3 is associated with cancer cells growth. It is important to mention that some drugs act as Smyd3 inhibitors in the treat some cancers. However, their interaction is very confusing; for this reason, the aim of this research was to evaluate the theoretical interaction of benzenesulfonamide and their derivatives (compounds 2 to 28) using 7o2c protein, novobiocin, BAY-6035, EPZ031686 and BCI-121 drugs as theoretical tools in DockingServer program. The results showed differences in the aminoacid residues involved in the interaction of benzenesulfonamide and their derivatives with 7o2c protein surface compared with novobiocin, BAY-6035, EPZ031686 and BCI-121 drugs. In additions, the inhibition constant (Ki) for benzenesulfonamide derivatives 2, 7, 8, 13, 14, 17, 20, 21, 24 and 28 was very lower compared to benzenesulfonamide, novobiocin, BAY-6035, EPZ031686 and BCI-121. In conclusion, the benzenesulfonamide derivatives 2, 7, 8, 13, 14, 17, 20, 21, 24 and 28 could be a good alternative as Smyd3 inhibitors to decrease cancer cells growth.El cáncer es un grave problema de salud pública a nivel mundial. Esta patología clínica está asociada a la activación/liberación de varias biomoléculas, entre ellas las proteínas de la familia Smyd. De esta forma, algunos estudios indican que Smyd3 está asociado con el crecimiento de células cancerosas. Es importante mencionar que algunos medicamentos actúan como inhibidores de Smyd3 en el tratamiento de algunos tipos de cáncer. Sin embargo, su interacción es muy confusa; por tal motivo, el objetivo de esta investigación fue evaluar la interacción teórica de la bencenosulfonamida y sus derivados (compuestos 2 al 28) utilizando como herramientas teóricas en el programa DockingServer la proteína 7o2c, novobiocina, BAY-6035, EPZ031686 y BCI-121. . Los resultados mostraron diferencias en los residuos de aminoácidos involucrados en la interacción de la bencenosulfonamida y sus derivados con la superficie de la proteína 7o2c en comparación con los fármacos novobiocina, BAY-6035, EPZ031686 y BCI-121. Además, la constante de inhibición (Ki) para los derivados de bencenosulfonamida 2, 7, 8, 13, 14, 17, 20, 21, 24 y 28 fue mucho menor en comparación con bencenosulfonamida, novobiocina, BAY-6035, EPZ031686 y BCI-121. En conclusión, los derivados de bencenosulfonamida 2, 7, 8, 13, 14, 17, 20, 21, 24 y 28 pueden ser una buena alternativa como inhibidores de Smyd3 para disminuir el crecimiento de células cancerosas.O câncer é um grave problema de saúde pública em todo o mundo. Esta patologia clínica está associada à ativação/liberação de várias biomoléculas, incluindo as proteínas da família Smyd. Desta forma, alguns estudos indicam que o Smyd3 está associado ao crescimento de células cancerígenas. É importante mencionar que algumas drogas atuam como inibidores de Smyd3 no tratamento de alguns tipos de câncer. No entanto, sua interação é muito confusa; por esta razão, o objetivo desta pesquisa foi avaliar a interação teórica de benzenossulfonamida e seus derivados (compostos 2 a 28) usando a proteína 7o2c, novobiocina, BAY-6035, EPZ031686 e drogas BCI-121 como ferramentas teóricas no programa DockingServer. Os resultados mostraram diferenças nos resíduos de aminoácidos envolvidos na interação da benzenossulfonamida e seus derivados com a superfície da proteína 7o2c em comparação com as drogas novobiocina, BAY-6035, EPZ031686 e BCI-121. Além disso, a constante de inibição (Ki) para os derivados de benzenossulfonamida 2, 7, 8, 13, 14, 17, 20, 21, 24 e 28 foi muito menor em comparação com benzenossulfonamida, novobiocina, BAY-6035, EPZ031686 e BCI-121. Em conclusão, os derivados de benzenossulfonamida 2, 7, 8, 13, 14, 17, 20, 21, 24 e 28 podem ser uma boa alternativa como inibidores de Smyd3 para diminuir o crescimento de células cancerígenas

Biochemical interaction of twenty steroid derivatives with ribosomal protein kinase 4 S6 (RSK-4) surface using a theoretical model

Several genetic expressions have been involved in the development of cancer such as the expression of a ribosomal kinase S6 P90 (RSK-4). It is important to mention that some compounds such as LJH685, 2073047-06-8, and SL0101 can act as RSK-4 inhibitors; however, its interaction with the surface of RSK-4 is very confusing. The aim of this research was to evaluate the interaction of twenty-nine steroid derivatives (1 to 29) with of RSK-4 surface using 6rv2 protein, LJH685, 2073047-06-8 and SL0101 as theoretical tools in the Dockingserver program. The results showed differences in the aminoacid residues involved in the interaction of steroid derivatives with 6rv2 protein surface compared with LJH685, 2073047-06-8 and SL0101. Besides, the inhibition constant for steroid derivatives 1, 12, 14, 19 and 22 was lower compared to 2073047-06-8 drug. In conclusion, the steroid derivatives 1, 12, 14, 19 and 22 could be a good alternative as RSK-4 inhibitors to decrease cancer cells growth

Comparative efficacy of two primary care interventions to assist withdrawal from long term benzodiazepine use: A protocol for a clustered, randomized clinical trial

<p>Abstract</p> <p>Background</p> <p>Although benzodiazepines are effective, long-term use is not recommended because of potential adverse effects; the risks of tolerance and dependence; and an increased risk of hip fractures, motor vehicle accidents, and memory impairment. The estimated prevalence of long-term benzodiazepine use in the general population is about 2,2 to 2,6%, is higher in women and increases steadily with age. Interventions performed by General Practitioners may help patients to discontinue long-term benzodiazepine use. We have designed a trial to evaluate the effectiveness and safety of two brief general practitioner-provided interventions, based on gradual dose reduction, and will compare the effectiveness of these interventions with that of routine clinical practice.</p> <p>Methods/Design</p> <p>In a three-arm cluster randomized controlled trial, general practitioners will be randomly allocated to: a) a group in which the first patient visit will feature a structured interview, followed by visits every 2-3 weeks to the end of dose reduction; b) a group in which the first patient visit will feature a structured interview plus delivery of written instructions to self-reduce benzodiazepine dose, or c) routine care. Using a computerized pharmaceutical prescription database, 495 patients, aged 18-80 years, taking benzodiazepine for at least 6 months, will be recruited in primary care health districts of three regions of Spain (the Balearic Islands, Catalonia, and Valencia). The primary outcome will be benzodiazepine use at 12 months. The secondary outcomes will include measurements of anxiety and depression symptoms, benzodiazepine dependence, quality of sleep, and alcohol consumption.</p> <p>Discussion</p> <p>Although some interventions have been shown to be effective in reducing benzodiazepine consumption by long-term users, the clinical relevance of such interventions is limited by their complexity. This randomized trial will compare the effectiveness and safety of two complex stepped care interventions with that of routine care in a study with sufficient statistical power to detect clinically relevant differences.</p> <p>Trial Registration</p> <p>Current Controlled Trials: <a href="http://www.controlled-trials.com/ISRCTN13024375">ISRCTN13024375</a></p

Don't erase

Aquesta exposició del Postgrau en Il·lustració creativa i tècniques de comunicació visual d’EINA és una mostra condensada de l’odissea personal que 26 il·lustradors hem fet durant un any. Us ensenyem fins a on hem arribat sota la consigna de “No esborrar”, d’abraçar l’error i perdre-li la por, de trobar la nostra manera única i intransferible d’il·lustrar. No hi ha camí ràpid per convertir-se en il·lustrador o il·lustradora d’èxit, igualment no hi ha una única manera d’il·lustrar. Cadascun de nosaltres ho fem i ho seguirem fent a la nostra manera, però el que està clar és que per il·lustrar bé necessites fer-ho sense por, amb confiança i seguretat en els encerts i també en els errors perquè això és el que fa que una obra ens emocioni.Esta exposición del Postgrado en Ilustración creativa y técnicas de comunicación visual de EINA es una muestra condensada de la odisea personal que 26 ilustradores hemos hecho durante un año. Os enseñamos hasta donde hemos llegado bajo la consigna de “No borrar”, de abrazar el error y perderle el miedo, de encontrar nuestra manera única e intransferible de ilustrar. No existe el camino rápido para convertirse en ilustrador o ilustradora de éxito, al igual que no hay una única forma de ilustrar, cada uno de nosotros lo hace y lo seguirá haciendo a su manera, pero lo que está claro es que para ilustrar bien necesitas hacerlo sin miedo, con confianza y seguridad en tus aciertos y también en tus errores porque eso es lo que hace que una obra nos emocione.This exhibition of the Postgraduate Diploma in Creative Illustration and Visual Communication Techniques of EINA is a condensed sample of the personal odyssey that 26 illustrators have made in the past year. In it we show you, the public, how far we have come under the slogan of “Don’t Erase”, of embracing error and facing our fears, of finding our unique and non-transferable way of illustrating. There is no quick way to become a successful illustrator, just as there is no single way to illustrate, each one of us will continue to work his or her own way, but what is clear is that to illustrate well you need to do it without fear, with confidence in both your achievements and failures because that is what helps create emotional, moving work